Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: 5 - You Need To See This

Despite Profit Fallout, GSK Remains Optimist For 2031 Revenue Target Amidst Cancer Drug Sale Rise

GSK's oncology sales increased 98% in 2024, and reflects strong demand and potentially new launches or indications for cancer therapies.

International Business Times UK

Is Exelixis a Biotech Stock Worth Adding to Your Portfolio?

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong stock performance. With a dedicated focus on cancer treatment innovation and an expanding market footprint, could EXEL be the next biotech stock to add to your portfolio? Read on to find out….

StockNews.com

Five ways to cut your risk of cancer – by an oncology consultant

Cancer is a complex disease with many causes – and sometimes none. For some patients, getting cancer is down to plain bad luck.

The Conversation

From analysis to the latest developments in health,
read the most diverse news in one place.

Is Exelixis Positioned to Capitalize on Emerging Cancer Therapies?

In the expanding oncology market, Exelixis (EXEL) is gaining attention with its strong pipeline and impressive stock performance. With a clear focus on cancer treatment innovation and a growing market presence, is the company set to lead the future of cancer care and treatment? Read more….

StockNews.com

Dr. Jonathan D’Cunha Brings Multifaceted Contributions to Cardiothoracic Surgery and Medical Education

Dr. Jonathan D'Cunha is a trailblazer in cardiothoracic surgery, widely respected for his clinical expertise, leadership, and dedication to advancing medical education. As Chair of Cardiothoracic Surgery at Mayo Clinic Arizona and Professor of ...

USA Today Sports Media Group

Demystifying CG Oncology: Insights From 7 Analyst Reviews

7 analysts have expressed a variety of opinions on CG Oncology (NASDAQ:CGON) over the past quarter, offering a diverse set of opinions from bullish to bearish.

Benzinga

Pfizer's New Chief Scientific Officer Charts R&D Vision For High And Low-Risk Investments

Pfizer's Chris Boshoff outlines plans to prioritize high-return projects, with a focus on obesity, Oncology, and oral GLP-1 therapies, amid Q3 growth.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

How Healthcare Leader Clara Latorre is Transforming Dermatology and Oncology Through Strategic Innovation

In today’s fast-paced healthcare world, few leaders balance clinical expertise and strategic innovation as seamlessly as Dr. Clara Latorre.

inkl

3 Healthcare Stocks Leading the Fight Against Global Diseases

As chronic and infectious diseases continue to rise, the demand for advanced healthcare solutions grows. Hence, investing in established healthcare stocks, Pfizer (PFE), Merck & Co (MRK), and AbbVie (ABBV), presents a compelling opportunity to capitalize on the sector’s landscape. Read on….

StockNews.com

3 Undervalued Health-Tech Stocks to Buy for Long-Term Growth

The health-tech industry’s long-term growth is fueled by the growing need for cutting-edge technologies to address critical areas, as well as the demand for personalized medicine. Thus, it could be wise to invest in fundamentally solid health-tech stocks McKesson (MCK), Cardinal Health (CAH), and Zimmer Biomet (ZBH) poised for long-term…

StockNews.com

This Biotech Stock Insider is Buying Shares, Should You?

This Nuvation Bio board member and longtime biotech industry insider carried out his first purchase since his appointment in January.

Barchart

Cancer vaccine breakthrough as tests show positive results on patients with tumours

The jab, known as mRNA-4359, is developed by Moderna

The Independent UK

China detains five AstraZeneca staff over ‘data privacy and import breaches’

Detentions involve Chinese citizens who marketed cancer drugs for firm’s oncology division

The Guardian - UK

3 Oncology Stocks With Major Upside

With the rising prevalence of chronic diseases, increasing cell and gene therapies, and rising tech adoption in the biotech industry, the oncology market is booming. Amid this backdrop, investors could consider quality biotech stocks Pyxis Oncology (PYXS), Immatics (IMTX), and Jazz Pharmaceuticals (JAZZ), having significant upside potential. Continue reading.

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

As Radiotherapy Redefines Cancer Care, Here's the Stock to Buy Near 52-Week Highs

A new generation of radiotherapies are redefining cancer care, offering the potential for a more powerful treatment with fewer side effects. It could become a mainstream therapy for the big "traditional" cancers that make the disease the leading cause of death worldwide, which is why Morgan Stanley forecast the radiopharma…

Top News

Man Arrested For Selling Counterfeit Cancer Drugs In Houston

Sanjay Kumar arrested in Houston for selling counterfeit cancer drugs in the U.S., facing serious charges for trafficking in fake oncology medications.

inkl

The future of cancer care: How advanced oncology solutions are changing the industry

Cancer is one of the most devastating diseases, affecting thousands of people every year. That is also why it is one of the most well-researched areas of healthcare, with medical professionals constantly looking for ways to adapt the latest technology developments to improve cancer detection and treatments

Barchart

5 Biotech Stocks Under $10 With Multibagger Potential

As the biotech industry continues to redefine the healthcare landscape, here are five penny biotech stocks poised for meteoric growth in this evolving industry.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

1 Biopharma Stock Setting the New Standard in Cancer Care Drugs

The annual conference of the American Society of Clinical Oncology is always the biggest event-making cancer conference. And this year, the attention-grabber was AstraZeneca, as its lung and breast cancer drugs significantly slowed the spread of disease in two trials, potentially establishing the medicines as the new standard of care…

The Guardian - UK

‘Off the charts’: the key breakthroughs giving new hope in treating cancer

World’s largest cancer conference in Chicago shares ‘impressive’ findings in vaccines, drug trials and AI

The Independent UK

Cancer patients say they were turned away from New Mexico hospital

‘They didn’t even try to make it work,’ one oncology patient said of Memorial Medical Center

StockNews.com

3 Pharma Stocks Delivering Exciting April Returns

The pharmaceutical industry is expected to grow rapidly due to the ever-rising healthcare needs, increasing demand for innovative medications, and technological advancements. Therefore, fundamentally strong pharmaceutical stocks Dr. Reddy’s (RDY), Teva Pharmaceutical Industries (TEVA), and AbbVie (ABBV) could be worth adding to your portfolio. Read on.

The Times of India

Advancing cancer care with emerging technology: A fine balance

The breakthroughs in cutting-edge medical technologies for cancer care are remarkable. It seems like every day we are reading about ground-breaking progress that can change the fundamental premise of medical care delivery. Wearable technology, molecular testing and point-of-care devices promise hospital-level care at home, but established technologies like robotic surgery…

Barchart

Up 825% So Far in 2024, Can This Penny Stock Go Any Higher?

Despite its outsized year-to-date gains, Wall Street expects this breakout penny stock to soar 55% higher, on average.

Barchart

Next-Gen Cancer Therapies Could Spark Upside for AstraZeneca Stock

Next-generation cancer therapies are here. AstraZeneca - already an oncology leader - is going down the path of radiopharmaceuticals with its purchase of Fusion. Along with the other potential blockbuster drugs in its pipeline, this should bode well for growth at AZN.

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

125 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.